This setup does not look like much — yet it keeps regenerating

What the system saw

We already own CRNX six times over. The Relative Strength Engine just told us to buy it again. Not a typo. Pull up the open positions and you'll count six separate CRNX entries — from day 1 through day 13 — all still open, all slightly positive. Now a seventh goes in at $84.79. Either this system has genuine conviction in this name, or this setup keeps regenerating every few days. Probably both. Here's why it keeps showing up. CRNX sits at the 98th percentile of relative strength over the last 63 days — top 2% of everything the engine scans. It's been holding that rank while the broader market has gone essentially nowhere today, SPY flat on the session. This morning, CRNX dipped right to its 20-day moving average at $84.01 and bounced. The low today was $84.68. The entry trigger is $84.79. That's a tight, controlled reclaim off a clean support level — exactly the moment the engine is built to catch.

Why our Relative Strength Engine liked it

The Relative Strength Engine hunts for stocks already outperforming the field — then waits for the moment they pull back just enough to offer a lower-risk entry before the next leg up. The 20-day moving average is its preferred line in the sand for this type of setup. When a top-decile RS name holds that level and turns, the score reflects it. CRNX scored 70.5 out of 100 here. The RS rank component alone contributed 36 points. Proximity to the 20dma added nearly 14 more. Volume dried up into the touch — another 10 points — and the stock held support cleanly for another 10. Mid-range conviction number, yes. But it's a tight, well-constructed score. Now, the fundamentals — and they're worth naming plainly, because they're ugly. CRNX is losing money: net margin around -12%, ROE of -44%, negative P/E, negative EV/EBITDA. A DCF model doesn't help here; it spits out a negative fair value. The Piotroski F-Score is 2 out of 9. This is a clinical-stage biotech burning cash. Analyst consensus is Buy, with an average target sitting right at current price — which isn't exactly a ringing endorsement from the Street. This isn't a fundamental long. It's a price-action trade on a high-momentum name the market has been rewarding in spite of the income statement. The Altman Z-Score of 39 at least says near-term bankruptcy risk is low. Beyond that, we're following the tape, not the balance sheet.

The trade plan

Entry: $84.79 Stop: $83.61 — that's $1.18 of risk per share, set just below the recent 20dma zone Target: $87.14 — 2R on the trade We're putting roughly $5,003 behind this one, 59 shares in the paper account. At a $1.18 stop, the risk is defined and contained — even on a name we're already carrying six times over. Those six prior CRNX positions, ranging from +0.1% to +1.0%, don't change how this entry gets evaluated. Each one was scored independently on the day it triggered. This one scored 70.5. That clears the system's threshold, so it goes in — same process, same rules.

Position size: our paper account is putting about $5,003 (59 shares) into this trade, sized to risk roughly $70 if our stop is hit. This is what the system committed in its paper account — not a suggestion of how much you should put into any trade.

What could go wrong

The clearest risk here is concentration. Seven positions in the same ticker is not diversification by any normal definition. If CRNX gaps down on a clinical readout or unexpected biotech news, all seven entries feel it at once. That's a real, compounded exposure — and it's worth sitting with before you look at this setup in isolation. At the trade level, the risk is simple: if price breaks below $83.61, the thesis — that the 20-day moving average is holding as support — is broken. The system exits. No debate, no override. Zooming out: we're on Day 31, up 1.6% while SPY is up 2.8% over the same window. We're trailing the benchmark. Win rate on closed trades is 0%, though every open position is currently in the green. Several names appear to be in an extended holding period. Results so far aren't conclusive in either direction — and that's an honest read of where things stand.

One more thought before we go

Seven entries in one ticker makes for a strange-looking portfolio on paper. But each one cleared the same filter on its own merits, independently, on the day it triggered. What's worth watching now is whether they all exit together — or whether the later entries catch a larger move than the earlier ones did. If that spread develops, it will tell us something real about how momentum setups can compound when a system keeps finding the same name at the same support level.